Qiagen NV (NYSE:QGEN) shares gapped up before the market opened on Monday . The stock had previously closed at $35.78, but opened at $37.07. Qiagen shares last traded at $38.01, with a volume of 2572188 shares trading hands.
Several research analysts recently issued reports on QGEN shares. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a research report on Friday, April 12th. Jefferies Financial Group reaffirmed a “neutral” rating on shares of Qiagen in a research report on Monday, January 21st. Zacks Investment Research lowered Qiagen from a “hold” rating to a “sell” rating in a research report on Tuesday, April 9th. UBS Group started coverage on Qiagen in a research report on Friday, March 15th. They set a “neutral” rating and a $42.00 target price on the stock. Finally, Goldman Sachs Group reaffirmed a “buy” rating on shares of Qiagen in a research report on Tuesday, May 7th. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $41.71.
The company has a quick ratio of 1.52, a current ratio of 1.69 and a debt-to-equity ratio of 0.54. The firm has a market cap of $8.36 billion, a price-to-earnings ratio of 28.37, a PEG ratio of 2.22 and a beta of 0.88.
Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. The business had revenue of $348.70 million for the quarter, compared to analyst estimates of $351.68 million. Qiagen had a return on equity of 12.22% and a net margin of 12.45%. The company’s revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.26 earnings per share. Research analysts anticipate that Qiagen NV will post 1.43 EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in the company. Slow Capital Inc. acquired a new position in shares of Qiagen in the first quarter valued at about $1,971,000. FMR LLC increased its holdings in shares of Qiagen by 2,731.6% in the first quarter. FMR LLC now owns 2,548,771 shares of the company’s stock valued at $103,518,000 after purchasing an additional 2,458,758 shares during the period. BlueMountain Capital Management LLC increased its holdings in shares of Qiagen by 20.4% in the first quarter. BlueMountain Capital Management LLC now owns 30,199 shares of the company’s stock valued at $1,224,000 after purchasing an additional 5,119 shares during the period. HighTower Advisors LLC increased its holdings in shares of Qiagen by 290.2% in the first quarter. HighTower Advisors LLC now owns 33,839 shares of the company’s stock valued at $1,377,000 after purchasing an additional 25,167 shares during the period. Finally, RMB Capital Management LLC increased its holdings in shares of Qiagen by 186.1% in the first quarter. RMB Capital Management LLC now owns 32,610 shares of the company’s stock valued at $1,326,000 after purchasing an additional 21,213 shares during the period. 64.24% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was first published by Highlight Press and is the property of of Highlight Press. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://highlightpress.com/2019/05/20/qiagen-qgen-shares-gap-up-to-37-07.html.
About Qiagen (NYSE:QGEN)
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.